Immunoadsorption in the treatment of pemphigus.
The autoimmune bullous skin disorder pemphigus is characterized by the presence of autoantibodies that target distinct adhesion molecules of the epidermis. The autoantibodies result in a loss of the epidermal adhesive properties, which in turn leads to the appearance of blisters and erosions on skin and mucosal surfaces. In the majority of cases, disease activity can be sufficiently controlled by systemic corticosteroids in combination with immunsuppressants, but pemphigus often is recalcitrant to conventional immunosuppressive therapy. Clinical remission can be obtained only in a minority of patients. In the past, only cyclophosphamide and high-dose intravenous immunoglobulin (IVIG) were available as second-line therapies. Meanwhile, immunoadsorption and monoclonal anti-CD 20 antibody rituximab have been established as further therapeutic options.
Department of Dermatology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Alexander.Mlynek@uniklinikum-dresden.de
Alexander
A
Mlynek
Michael
M
Meurer
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D001781:Blood Component Removal / Q000379:methods*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010392:Pemphigus / Q000097:blood / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069283:Rituximab